Re-design the Supply Chain.pptx
- 1. : TOPIC NAME : Re-designthe Supply Chain : TOPIC NAME : Re-design the Supply Chain Student Name:- Abhishek Borkar Class- B- pharm 4th year Shraddha Institute of Pharmacy Kondala zambre , Washim-444505
- 2. Supporting us to deliver seamless, convenient, accessible, affordable and safe medications at every point of care
- 3. Confident & competent Pharmacy Workforce Re-design supply chain & streamline processes Centralise procurement, packaging, compounding and distributon Deliver medications when patients need it, where patients need it healthcare profession als & patients seamless care& innovations Technolog y Information People Process Enhance policy to improve model of care
- 4. Centralised procurement, packaging, compounding and distribution Current Landscape
- 5. Centralised Sterile Drug Compounding Hub-and-Spoke Model A“Hub-and-Spaoke” business model to achieve system benefits Improved Medication Safety Improved Staff Safety Build System Resiliency & Continuity Build National Compounding Capability Enable Pandemic Preparedness Cost Savings
- 6. ESTABLISHING A CENTRALISED STERILE COMPOUNDING SERVICE Introduction: - The National Pharmacy Strategy (NPS) is a 10-year plan to transform the delivery of pharmaceutical care and medication management in Singapore that was approved by the Ministry of Health (MOH) In 2017, MOH approved the implementation of the Hub-and- Spoke compounding and distribution model to provide centralised sterile drug compounding service in the Singapore public healthcare sector. Establishing a centralised sterile compounding service is an initiative under the NPS Thrust 3, Re-design Supply Chain.
- 7. Objectives Maximise economic benefits by leveraging on technology / robotics to address key concerns such as medication and staff safety, productivity, shrinking local workforce, quality assurance and evolving models of care Strengthen the public healthcare sector’s system-level resilience to achieve continual supply of sterile compounded drug product
- 8. Method Hub-and-Spoke Sterile Drug Compounding Model A total of three non-cytotoxic (Fig. 1) and two cytotoxic hubs (Fig. 2) are proposed to cater to the needs of public healthcare institution. The hubs will be developed to Good Manufacturing Practice (GMP) standards to protect the interests of patients, reduce the level of risk inherent in large- scale production of drugs and achieve consistent high quality manufacturing standards. The Pharmaceutical Inspection Co-operation Scheme (PIC/S) GMP standards is an internationally recognised quality assurance system in drug manufacturing to ensure the quality of drug products
- 9. Fig. 1: Proposed three non-cytotoxic hubs Fig. 2: Proposed two cytotoxic hubs
- 10. Risk Assessment :- Sterile drug compounding is a known high risk activity. Failure Mode Effect Analysis (FMEA) has been undertaken to determine potential points of failure to the sterile compounding process and to identify possible measures to prevent/mitigate these failures. Table 1 shows the possible failure modes in the sterile compounding process and the risk priority number assigned. The continuous risk assessment approach is central to the principles of GMP. Competency Building:- In parallel, to build competency in sterile compounding, a Centralised Drug Compounding Workgroup was formed in 2017, helmed by the Chief Pharmacist of Singapore. This workgroup has also been working on the harmonisation of various components of sterile drug compounding Discuss and flag practice issues, serve as expert panel to Governance Committee Develop national training programme – Pharmaceutical Societyof Singapore Sterile Compounding Programme Harmonise formulae & standard operating procedures Develop list of productsto be compounded by hubs, service level agreements Functions of the Centralised Drug Compounding Workgroup
- 11. PHI s Compounding HUBs GPs (CHAS) ILTC s Patients at Home Other Collection Central Warehouse, Central Fill Pharmacy and Packaging Procureme nt
- 12. Formation of ALPS Short term goals Provide cost effective and reliable procurement, warehousing, supply chain and site operation services Reap system level gains for patients, providers and staff through economies of scale, stronger procurement capabilities and integrated supply chain management Develop strategic and innovative capabilities, to optimise procurement and supply chain models, and lower costs at the system level . Provide more development and opportunities for procurement and supply chain staff Enable new services and partnerships, and drive care transformation to achieve our vision of shifting care out of our institutions into the community (e.g. GPs, VWO nursing homes, other community based providers)
- 13. Centrally Managed Warehousing and Distribution for Polyclinics Current polyclinics supply chain landscape: Fragmented 2019 Centrally Managed Warehousing and Distribution for Polyclinics – Managed by ALPS 1. Stocks owned by ALP to optimise stock holding and manage associated risk e.g. inventory obsolescence. 2. 2. Provide End-to-End services • Procurement • Warehouse Management • Supplier Management
- 14. Deliver Medication When Patients Need It, Where Patients Need It Current Home Delivery Services Hospital, pharmacy and polyclinic
- 15. THANK YOU